Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast CancerShaokun Shu, Kornélia Polyák, Hua‐Jun Wu et al.|Molecular Cell|2020Cited by 207
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumorsPaloma Cejas, Ramesh A. Shivdasani, Carlos Fernández-del Castillo et al.|Nature Medicine|2019Cited by 185
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activityApril C. Watt, Shom Goel, Paloma Cejas et al.|Nature Cancer|2020Cited by 110
FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissuesAlba Font‐Tello, Henry W. Long, Nikolas Kesten et al.|Nature Protocols|2020Cited by 36
Heterogeneity and transcriptional drivers of triple-negative breast cancerBojana Jovanović, Kornélia Polyák, Daniel Temko et al.|Cell Reports|2023Cited by 29